

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 57389

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

Shafiq M *et al.* PCSK9 inhibitor effects on fatty liver

Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson, Yousaf Zafar

Match Overview

1	Internet 36 words crawled on 12-Oct-2020 academic.oup.com	1%
2	Internet 26 words crawled on 19-Aug-2020 mafiadoc.com	1%
3	Crossref 20 words Grace Earl. "PCSK9 inhibitors", <i>Nursing Critical Care</i> , 2018	1%
4	Internet 18 words crawled on 27-Aug-2020 www.wjgnet.com	1%
5	Internet 15 words crawled on 17-Nov-2017 www.uptodate.com	<1%
6	Internet 13 words crawled on 25-May-2020 www.mdpi.com	<1%



Effects of proprotein convertase subtilisin/kexin type – 9 inhibitors on fat



Sign in



ALL

IMAGES

VIDEOS

35,400 Results

Any time ▼

The effects of proprotein convertase subtilisin/kexin type ...

<https://www.ncbi.nlm.nih.gov/pubmed/30551367>

Recently, **proprotein convertase subtilisin/kexin type 9** (PCSK9) **inhibitors** have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial **effects** on cardiovascular disease ...

Cited by: 2

Author: Patchareeya Amput, Christian McSweene...

Publish Year: 2019

[PDF] Proprotein convertase subtilisin/Kexin type-9 (PCSK-9 ...

<https://www.tandfonline.com/doi/pdf/10.1080/20009666.2019.1710952>

fish oil, garlic and plant sterols. Proprotein convertase subtilisin/Kexin type-9 inhibitors (PCSK-9), a new medication for hyperlipidemia, slow the progression of atherosclerosis and prevent death in CAD with an **effect as 70% that of a statin**. Statin is a prototype of cholesterol-lowering medications and famous in CAD prevention and progression.

Search Tools

Turn off Hover Translation (关闭取词)

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors o



Sign in



ALL

IMAGES

VIDEOS



Add the Give with Bing extension >

37,800 Results

Any time ▾

[PDF] [Proprotein convertase subtilisin/Kexin type-9 \(PCSK-9 ...](#)

<https://www.tandfonline.com/doi/pdf/10.1080/20009666.2019.1710952>

fish oil, garlic and plant sterols. Proprotein convertase subtilisin/Kexin type-9 inhibitors (PCSK-9), a new medication for hyperlipidemia, slow the progression of atherosclerosis and prevent death in CAD with an **effect as 70% that of a statin**. Statin is a prototype of cholesterol-lowering medications and famous in CAD prevention and progression.

Author: Yousuf Zafar, Yasar Sattar, Waqas Ullah... **Publish Year:** 2020

[The effects of proprotein convertase subtilisin/kexin type ...](#)

<https://www.sciencedirect.com/science/article/pii/S0753332218347188>

Jan 01, 2019 · Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for **cholesterol regulation**. **PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C.**

Cited by: 2

Author: Patchareeya Amput, Christian McSweeney, ...

Publish Year: 2019

[Liver-Targeted Small-Molecule Inhibitors of Proprotein ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29073340>

Search Tools

Turn on Hover Translation (开启取词)

激活 Windows

转到“设置”以激活 Windows

Feedback

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

72,000 Results

Any time ▾

[The effects of proprotein convertase subtilisin/kexin type ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/30551367>

Recently, **proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors** have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial **effects** on cardiovascular disease ...

Cited by: 2

Author: Patchareeya Amput, Christian McSweeney, ...

Publish Year: 2019

[The effects of proprotein convertase subtilisin/kexin type ...](#)

<https://www.sciencedirect.com/science/article/pii/S0753332218347188>

Jan 01, 2019 · Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for **cholesterol regulation**. **PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C.**

Cited by: 2

Author: Patchareeya Amput, Christian McSweeney, ...

Publish Year: 2019

[Liver-Targeted Small-Molecule Inhibitors of Proprotein ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29073340>

Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis
Angew Chem Int Ed Engl . 2017 Dec 18;56(51):16218-16222. doi: 10.1002/anie.201708744.

Cited by: 11

Author: Kim F. McClure, David W. Piotrowski, Donn...

Publish Year: 2017

PEOPLE ALSO ASK

Can PCSK9 inhibitors cause high cholesterol? ▾

Can PCSK9 be taken with statins? ▾

How to take PCSK9 inhibitor? ▾